China China Manufacturer for Doxycycline Hyclate 20 Mg - Niraparib 1038915-60-4 – CPF manufacturers and suppliers

China Manufacturer for Doxycycline Hyclate 20 Mg - Niraparib 1038915-60-4 – CPF

Short Description:

Product Detail

Product Tags

Feedback (2)

We believe that long time period partnership is a result of top of the range, value added services, rich expertise and personal contact for Sugammadex Sodium, Ticagrelor Uses, Tofacitinib Supplier, Together with our efforts, our products and solutions have won the trust of clients and been very salable each here and abroad.

China Manufacturer for Doxycycline Hyclate 20 Mg - Niraparib 1038915-60-4 – CPF Detail:

Description

Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.

In Vitro

Niraparib (MK-4827) inhibits PARP activity with EC50=4 nM and EC90=45 nM in a whole cell assay. MK-4827 inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. MK-4827 displays excellent PARP 1 and 2 inhibition with IC50=3.8 and 2.1 nM, respectively, and in a whole cell assay[1]. To validate that Niraparib (MK-4827) inhibits PARP in these cell lines, A549 and H1299 cells are treated with 1 μM MK-4827 for various times and measured PARP enzymatic activity using a chemiluminescent assay. The results show that Niraparib (MK-4827) inhibits PARP within 15 minutes of treatment reaching about 85% inhibition in the A549 cells at 1 h and about 55% inhibition at 1 h for the H1299 cells.

Niraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vd_ss=6.9 L/kg), long terminal half-life (t_1/2=3.4 h), and excellent bioavailability, F=65%^[1]. Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily^].

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Chemical structure

Niraparib 1038915-60-4

2018 GMP-2
原料药GMP证书201811（captopril ,thalidomide etc）
GMP-of-PMDA-in-Chanyoo-平成28年08月03日　Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect.

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.

VIEW MORE

VIEW MORE

International cooperation

Domestic cooperation

Product detail pictures:

Related Product Guide:

Sticking to the principle of "Super High-quality, Satisfactory service" ,We are striving to generally be a very good business partner of you for China Manufacturer for Doxycycline Hyclate 20 Mg - Niraparib 1038915-60-4 – CPF , The product will supply to all over the world, such as: Bandung, Israel, Berlin, During the 10 years of operating, our company always try our best to bring consumption satisfaction for user, built a brand name for ourselves and a solid position in the international market with major partners come from many countries such as Germany, Israel, Ukraine, United Kingdom, Italy, Argentina, France, Brazil, and so on. Last but not least, price of our products are very suitable and have fairly high competition with other companies.

Brilinta Ticagrelor